Related references
Note: Only part of the references are listed.Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
John M. L. Ebos et al.
CANCER CELL (2009)
Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis
Marta Paez-Ribes et al.
CANCER CELL (2009)
A PILOT SAFETY STUDY OF LENALIDOMIDE AND RADIOTHERAPY FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME
Jan Drappatz et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2009)
Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma
Teri N. Kreisl et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma
Andrew D. Norden et al.
JOURNAL OF NEURO-ONCOLOGY (2009)
Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival
Ashwatha Narayana et al.
JOURNAL OF NEUROSURGERY (2009)
VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer
Elizabeth R. Gerstner et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2009)
Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide
Walter Taal et al.
CANCER (2008)
HIF1α induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion
Rose Du et al.
CANCER CELL (2008)
Pathways Mediating Resistance to Vascular Endothelial Growth Factor - Targeted Therapy
Lee M. Ellis et al.
CLINICAL CANCER RESEARCH (2008)
Antiangiogenic therapy in malignant gliomas
Andrew D. Norden et al.
CURRENT OPINION IN ONCOLOGY (2008)
The Emerging Role of Anti-Angiogenic Therapy for Malignant Glioma
David A. Reardon et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2008)
Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: Interim analysis of safety and tolerability
Albert Lai et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2008)
Feasibility of using bevacizumab with radiation therapy and temozolomide in newly diagnosed high-grade glioma
Ashwatha Narayana et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2008)
Correlation of O6-Methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity
Monika E. Hegi et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Randomized Phase II Study of Cilengitide, an Integrin-Targeting Arginine-Glycine-Aspartic Acid Peptide, in Recurrent Glioblastoma Multiforme
David A. Reardon et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan
Sith Sathornsumetee et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase II study of imatinib in patients with recurrent gliomas of various histologies: A European organisation for research and treatment of cancer brain tumor group study
Eric Raymond et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas
Dieto Brandsma et al.
LANCET ONCOLOGY (2008)
A quantitative analysis of kinase inhibitor selectivity
Mazen W. Karaman et al.
NATURE BIOTECHNOLOGY (2008)
Bevacizumab for recurrent malignant gliomas - Efficacy, toxicity, and patterns of recurrence
A. D. Norden et al.
NEUROLOGY (2008)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Molecular origins of cancer: Tumor angiogenesis
Robert S. Kerbel
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Malignant gliomas in adults
Patrick Y. Wen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Bevacizumab/Irinotecan. An active treatment for recurrent high grade gliomas: Preliminary results of an ANOCEF Multicenter Study
S. Guiu et al.
REVUE NEUROLOGIQUE (2008)
Response criteria for glioma
A. Gregory Sorensen et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2008)
Modes of resistance to anti-angiogenic therapy
Gabriele Bergers et al.
NATURE REVIEWS CANCER (2008)
The role of myeloid cells in the promotion of tumour angiogenesis
Craig Murdoch et al.
NATURE REVIEWS CANCER (2008)
Integrins in angiogenesis and lymphangiogenesis
Christie J. Avraamides et al.
NATURE REVIEWS CANCER (2008)
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
Kathy Miller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors
Howard A. Fine et al.
CLINICAL CANCER RESEARCH (2007)
Medical management of brain tumor patients
Jan Drappatz et al.
NEUROLOGIC CLINICS (2007)
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme
James J. Vredenburgh et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography:: A pilot study
Wei Chen et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
MRI of tumor angiogenesis
Tristan Barrett et al.
JOURNAL OF MAGNETIC RESONANCE IMAGING (2007)
Angiogenesis in brain tumours
Rakesh K. Jain et al.
NATURE REVIEWS NEUROSCIENCE (2007)
Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults
Santosh Kesari et al.
NEURO-ONCOLOGY (2007)
A phase I trial of sorafenib (BAY 43-9006) for patients with recurrent or progressive malignant glioma (NABTT 0401)
L. B. Nabors et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects
Dan G. Duda et al.
TRENDS IN MOLECULAR MEDICINE (2007)
Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma
L. Burt Nabors et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas
Annick Desjardins et al.
JOURNAL OF NEURO-ONCOLOGY (2007)
Relationship between survival and edema in malignant gliomas: Role of vascular endothelial growth factor and neuronal pentraxin 2
Marc R. J. Carlson et al.
CLINICAL CANCER RESEARCH (2007)
Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma
James J. Vredenburgh et al.
CLINICAL CANCER RESEARCH (2007)
Effect of bevacizumab on radiation necrosis of the brain
Javier Gonzalez et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2007)
Sorafenib in advanced clear-cell renal-cell carcinoma
Bernard Escudier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients
Tracy T. Batchelor et al.
CANCER CELL (2007)
The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme
Karla V. Ballman et al.
NEURO-ONCOLOGY (2007)
Imaging of angiogenesis: Clinical techniques and novel imaging methods
James M. Provenzale
AMERICAN JOURNAL OF ROENTGENOLOGY (2007)
Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition
Henk. M. W. Verheul et al.
NATURE REVIEWS CANCER (2007)
Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma
Marc C. Chamberlain et al.
JOURNAL OF NEURO-ONCOLOGY (2007)
Opinion - Angiogenesis: an organizing principle for drug discovery?
Judah Folkman
NATURE REVIEWS DRUG DISCOVERY (2007)
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
Alan Sandler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Medical management of patients with brain tumors
Patrick Y. Wen et al.
JOURNAL OF NEURO-ONCOLOGY (2006)
The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; A review
Ferry A. L. M. Eskens et al.
EUROPEAN JOURNAL OF CANCER (2006)
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
George D. Demetri et al.
LANCET (2006)
Tumor stromal-derived factor-1 recruits vascular progenitors to mitotic neovasculature, where microenvironment influences their differentiated phenotypes
Manish Aghi et al.
CANCER RESEARCH (2006)
Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08
Patrick Y. Wen et al.
CLINICAL CANCER RESEARCH (2006)
Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker
Nola Hylton
JOURNAL OF CLINICAL ONCOLOGY (2006)
Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: Current status and future directions
Alessandro Morabito et al.
ONCOLOGIST (2006)
Mechanisms of angiogenesis in gliomas
O. Kargiotis et al.
JOURNAL OF NEURO-ONCOLOGY (2006)
Combination chemotherapy with 13-cis-retinoic acid and celecoxib in the treatment of glioblastoma multiforme
V. A. Levin et al.
JOURNAL OF NEURO-ONCOLOGY (2006)
MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy
WB Pope et al.
NEUROLOGY (2006)
Platelet-derived growth factor (PDGF) and glial tumorigenesis
AH Shih et al.
CANCER LETTERS (2006)
Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastorna multiforme
DA Reardon et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: Continued experience of a phase I trial in rectal cancer patients
CG Willett et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series
G Dresemann
ANNALS OF ONCOLOGY (2005)
Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis
R Abounader et al.
NEURO-ONCOLOGY (2005)
Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer
AL Thomas et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
UKT-04 trial of continuous metronomic low-dose chemotherapy with methotrexate and cyclophosphamide for recurrent glioblastoma
U Herrlinger et al.
JOURNAL OF NEURO-ONCOLOGY (2005)
Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma
DA Reardon et al.
CANCER (2005)
Continuous low-dose chemotherapy plus inhibition of cyclooxygenase-2 as an antiangiogenic therapy of glioblastoma multiforme
J Tuettenberg et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2005)
Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma
DA Reardon et al.
NEURO-ONCOLOGY (2004)
Combined thalidomide and temozolomide treatment in patients with glioblastoma multiforme
F Baumann et al.
JOURNAL OF NEURO-ONCOLOGY (2004)
Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme
SM Chang et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2004)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
H Hurwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Suramin and radiotherapy in newly diagnosed glioblastoma: Phase 2 NABTT CNS Consortium study
JJ Laterra et al.
NEURO-ONCOLOGY (2004)
Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: Final report of NABTT 97-11
TT Batchelor et al.
NEURO-ONCOLOGY (2004)
The anti-angiogenic basis of metronomic chemotherapy
RS Kerbel et al.
NATURE REVIEWS CANCER (2004)
Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas
HA Fine et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins αvβ3 and αvβ5 in patients with advanced solid tumours
FALM Eskens et al.
EUROPEAN JOURNAL OF CANCER (2003)
Cyclooxygenase-2:: a therapeutic target in angiogenesis
MA Iñiguez et al.
TRENDS IN MOLECULAR MEDICINE (2003)
VEGF-Trap: A VEGF blocker with potent antitumor effects
J Holash et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Phase II study of Thalidomide in the treatment of recurrent glioblastoma multiforme
GM Marx et al.
JOURNAL OF NEURO-ONCOLOGY (2001)
Thalidomide as an anti-angiogenic agent in relapsed gliomas
SC Short et al.
JOURNAL OF NEURO-ONCOLOGY (2001)
Angiogenesis in cancer and other diseases
P Carmeliet et al.
NATURE (2000)
Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption
JL Rubenstein et al.
NEOPLASIA (2000)
A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse
WKA Yung et al.
BRITISH JOURNAL OF CANCER (2000)
Share Paper
